Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS
pharmaceutical investing Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS (eflapegrastim) Data
Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units
